Stáhnout kapitolu v PDF

Autoři: Jiří Masopust, Miloslav Kopeček, Dita Protopopová

Garanti: Tomáš Kašpárek, Libor Ustohal

Oponent: Pavel Mohr

 

Stabilizační a udržovací léčba schizofrenie

Vysvětlivky:
ovál - nadpis 
kosočtverec - výběr z více variant
přerušovaná čára - diagram pokračuje na další straně 

Nežádoucí účinky navozené antipsychotiky

Tabulka 1 Relativní frekvence nejčastějších NÚ antipsychotik (upraveno dle Hassan et al. 2013, Galletly et al. 2016, Leucht et al. 2017, Leucht et al. 2013)

 Tabulka 1

Tabulka 2 - intervence u nežádoucích účinků navozených antipsychotiky

Tabulka 2

Literatura

Baskak B, Atbasoglu EC, Ozguven HD, Saka MC, Gogus AK.The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2007;27(3):289-94.

Caemmerer J, Correll CU, Maayan L.Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159-68.

Correll CU, Maayan L, Kane J, Hert MD, Cohen D. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2016;77(6):e746-56.

de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976;33(5):599-602.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-72.

Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006;163(3):494-9.

Gugger JJ Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659-71.

Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, Lykouras L. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332-41.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016; 315(22):2424-34.

Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, Lerner PP, Bergman J, Lerner V. ;Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol. 2016;36(3):200-5.

Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006 r;21(2):99-103.

Kreinin A, Miodownik C, Sokolik S, Shestakova D, Libov I, Bergman J, Lerner V.Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. World J Biol Psychiatry. 2011;12(8):620-6

Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, Delgado JF, Diez T, Villardaga I. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383-8.

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-403.

Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1989;9(6):403-6.

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017 May 25:appiajp201716121358. [Epub ahead of print]

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.

Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004, (4):CD001946.

Lin CC, Bai YM, Wang YC, Chen TT, Lai IC, Chen JY, Chen SY, Gau SS, Liou YJ. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29(6):529-36.

Lindenmayer JP, Tedeschi F, Yusim A, Khan A, Kaushik S, Smith RC, Parakadavil M. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia. Clin Schizophr Relat Psychoses. 2012;5(4):185-92. doi: 10.3371/CSRP.5.4.2.

Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol. 2006;29(2):68-72.

Maršálek M. Extrapyramidové polékové poruchy in Seifertová et al. Postupy v léčbě psychických poruch: algoritmy České neuropsychofarmakologické společnosti. Praha: Academia Medica Pragensis, 2008.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-56.

Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301.

Paton C, Esop R. Managing clozapine-induced neutropenia with lithium. Psychiatric Bulletin 2005; 29: 186–188.

Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003;23(3):305-8.

Pujalte D, Bottaï T, Huë B, Alric R, Pouget R, Blayac JP, Petit P. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236-42.

Rathbone J, Soares-Weiser K Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006 18;(4):CD003727.

Reinstein MJ, Sirotovskaya LA, Chasanov MA. Comparative Efficacy and Tolerability of Benzatropine and Terazosin in the Treatment of Hypersalivation Secondary to Clozapine. Clin. Drug Investig. (1999) 17: 97.

Seifertová D. Život ohrožující situace v Seifertová et al. Postupy v léčbě psychických poruch: algoritmy České neuropsychofarmakologické společnosti. Praha: Academia Medica Pragensis, 2008.

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947-56.

Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol. 2010;33(5):219-22.

Sultan RS, Olfson M, Correll CU, Duncan EJ. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. J Clin Psychiatry. 2017 [Epub ahead of print]

Švestka J. Clozapin: prototyp antipsychotik nové generace. 1998, Maxdorf, Praha.

Terevnikov V, Stenberg JH, Tiihonen J, Burkin M, Joffe G. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics. Nord J Psychiatry. 2017;71(1):77-80.

Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, Barr AM. Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol. 2014;29(3):125-37.

Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-94

Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, Hong CH, Seok JH, Park IH, Son SJ, Roh D, Kim BR, Lee BO. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. Clin Neuropharmacol. 2016;39(6):288-294.

Zheng W, Wang S, Ungvari GS, Ng CH, Yang XH, Gu YH, Li M, Xiang YQ, Xiang YT. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2017;37(3):341-346.

Reference

Balzan RP, Delfabbro PH, Galletly CA, et al. (2014) Metacognitive training for patients with schizophrenia: Preliminary evidence for a targeted, single-module programme. Australian and New Zealand Journal of Psychiatry 48: 1126–1136.


British Psychological Society. New Ways of Working for Applied Psychologists in Health and Social Care – The End of the Beginning. Leicester: British Psychological Society, Leicester; 2007.

Crawford MJ, Killaspy H, Barnes TR, et al. (2012) Group art therapy as an adjunctive treatment for people with schizophrenia: A ran- domised controlled trial (MATISSE). Health Technology Assessment 16(8): iii–iv, 1–76.

Chilvers R, Macdonald G and Hayes A (2006) Supported housing for people with severe mental disorders. The Cochrane Database of Systematic Reviews 4: CD000453.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50: 410-472.

Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77-89.

Killaspy H, Kingett S, Bebbington P, Blizard R, Johnson S, Nolan F, et al. Randomised evaluation of assertive community treatment: 3-Year outcome. British Journal of Psychiatry 2009; 195: 81-82.

Kinoshita Y, Furukawa TA, Kinoshita K, et al. (2013) Supported employment for adults with severe mental illness. The Cochrane Database of Systematic Reviews 9: CD008297.

Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl) 2017; 234: 2113-2125.

Komatsu, H., Y. Sekine, N. Okamura, N. Kanahara, K. Okita, S. Matsubara, T. Hirata, T. Komiyama, H. Watanabe and Y. Minabe. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: A randomized controlled trial. Schizophr Res 2013; 150: 240-244.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.

Malone D, Marriott S, Simmonds S, Tyrer P, Malone D, Marriott S et al. Community mental health teams (CMHTs) for people with severe mental illnesses and distordered personality. Cochrane database of Systematic Reviews 2010, 3, Art. No. CD000270.

Marsh PJ, Langdon R, Harris A, et al. (2013) The case for social-cognitive remediation in schizophrenia: A life well lived is more than remission from psychosis. Australian and New Zealand Journal of Psychiatry 47: 512–515.

Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev. , 2011;4:CD001089

Marshall, M, Rathbone, J. Early intervention for psychosis. Cochrane Database of Systematic Reviews 2011, (6). Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004718.pub3/abstract

Orfanos S, Banks C, Priebe S. Are Group Psychotherapeutic Treatments Effective for Patients with Schizophrenia? A Systematic Review and Meta-Analysis. Psychother Psychosom 2015; 84: 241-249.

Pitt V, Lowe D, Hill S, et al. (2013) Consumer-providers of care for adult clients of statutory mental health services. The Cochrane Database of Systematic Reviews 3: CD004807.

Sin J and Norman I (2013) Psychoeducational interventions for family members of people with schizophrenia: A mixed-method systematic review. Journal of Clinical Psychiatry 74: e1145–e1162.

Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, Carvalho AF, Correll CU. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr 2017 Feb 9:1-12. doi: 10.1017/S1092852916000638.

Spaniel F, Bakstein E, Anyz J, Hlinka J, Sieger T, Hrdlicka J, Görnerová N, Höschl C.Relapse in schizophrenia: Definitively not a bolt from the blue. Neurosci Lett 2016; S0304-3940(16)30265-8.

Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.
Schizophr Res 2012; 134: 219-225.

Tosato S, Albert U, Tomassi S, Iasevoli F, Carmassi C, Ferrari S, Nanni MG, Nivoli A, Volpe U, Atti AR, Fiorillo A. A Systematized Review of Atypical Antipsychotics in Pregnant Women: Balancing Between Risks of Untreated Illness and Risks of Drug-Related Adverse Effects. J Clin Psychiatry 2017; 78(5):e477-e489.

Wykes T, Huddy V, Cellard C, et al. (2011) A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. The American Journal of Psychiatry 168: 472–485.

Wykes T, Steel C, Everitt B, et al. (2008) Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin 34: 523–537.

Xia J, Merinder LB and Belgamwar MR (2011) Psychoeducation for schizophrenia. The Cochrane Database of Systematic Reviews 6: CD00283

Datum zveřejnění: 20.9.2018